RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2001; 21(1): 059-068
DOI: 10.1055/s-2001-13120
DOI: 10.1055/s-2001-13120
Movement Disorders Induced by Dopamine Blocking Agents
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
31. Dezember 2001 (online)
ABSTRACT
Movement disorders are frequently due to dopamine blocking agents (DBAs) prescribed for psychiatric illnesses. DBAs are sometimes also prescribed inappropriately for other maladies. These drugs can cause a wide variety of involuntary movements, sometimes in combination. When these appear in the setting of psychiatric illnesses, the association is easy to recognize but the treatment remains a difficult problem. However, in other situations the diagnosis may be missed for extended periods of time, resulting in unnecessary diagnostic work-up and inappropriate therapy. The diagnosis depends on a compulsive drug history not only from the patient but also from patient's family, primary physician, and the pharmacist. The treatment options include removal of the offending agent or substitution with an atypical neuroleptic. Symptomatic treatments are varied and have an inconsistent effect on the movement disorders. Prevention remains the most important strategy.
KEYWORD
Tardive dyskinesia - antipsychotic drugs - schizophrenia - risk factors - pathophysiology - treatment - drug-induced parkinsonism - dopamine blocking agents
REFERENCES
- 1 Delay J, Deniker P. Chlorpromazine and neuroleptic treatment in psychiatry. J Clin Exp Psychopathol . 1956; 17 19-24
- 2 Uhrbrand L, Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacology (Berl) . 1960; 1 408-418
- 3 Tolosa E, Alom J, Marti M J. Drug-induced dyskinesias. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders
2nd ed. Baltimore: Williams & Wilkins 1993: 375-397
MissingFormLabel
- 4 Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol . 1972; 202 94-103
- 5 Suzuki T, Koizumi J, Moroji T. Clinical characteristics of the Pisa syndrome. Acta Psychiatr Scand . 1990; 82 454-457
- 6 Nealer R, Gerhardt S, Liebman J M. Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesia in the squirrel monkeys. Psychopharmacology (Berl). 1984; 82 20-26
- 7 Marsden C D, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med . 1980; 10 55-72
- 8 Hardie R J, Lees A J. Neuroleptic induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Neurology . 1987; 37 850-854
- 9 Stephen P J, Williamson J. Drug-induced parkinsonism in the elderly. Lancet . 1984; 2 1082-1083
- 10 Masso J F, Poza J J. Druginduced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia . 1996; 11 10-15
- 11 Mutch W J, Dingwall-Fordyce I, Downie A W. Parkinson's disease in a Scottish city. Br Med J . 1986; 292 534-536
- 12 Sethi K D, Patel B, Meador K J. Metoclopramide-induced parkinsonism. South Med J . 1989; 82 1581-1582
- 13 Korczyn A D, Goldberg G J. Extrapyramidal effects of neuroleptics. J Neurol Neurosurgery Psychiatry . 1976; 39 866-869
- 14 Gartmann J, Hartmann K, Kuhn M. Sanz-Streitlicht Nr 14. Schweiz Arzt Ztg . 1993; 29 1163-1164
- 15 Sethi K D, Zamrini E Y. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci . 1990; 2 64-66
- 16 Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord . 1997; 12 302-305
- 17 Decina P, Caracci G, Scapichio P L. The rabbit syndrome. Mov Disord . 1990; 5 263-266
- 18 Farde L, Wiesel F A, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry . 1988; 45 71-76
- 19 Bunney B S. Antipsychotic drug effects on the electrical activity of dopaminergic neurones. Trends Neurosci . 1984; 7 212-215
- 20 Casey D. Neuroleptic induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am . 1993; 16 589-610
- 21 Reches A, Burke R E, Kuker C M. Tetrabenazine, an awine-depleting drug, also block dopamine receptors. J Pharmacol Exp Ther . 1983; 225 515-521
- 22 Goetz C G. Drug-induced parkinsonism and idiopathic Parkinson's disease. Arch Neurol . 1983; 40 325-326
- 23 Marti Masso F J, Carrera N, Urtasun M. Drugs inducing parkinsonism in our environment [abstract]. J Neurol Neurosurg Psychiatry . 1991; 54 1025
- 24 Rajput A H, Rozdilsky B, Hornykiewikcz O. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol . 1982; 39 644-646
- 25 Klawans H L, Bergan D, Bruyn G W. Prolonged drug induced parkinsonism. Confin Neurol . 1973; 35 368-377
- 26 Burn D J, Brooks D J. Nigral dysfunction in drug-induced parkinsonism: an 18fluorodopa PET study. Neurology . 1993; 43 552-556
- 27 Kelly J T, Zimmerman R L, Abuzzahab F S, Schiele B C. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug induced parkinsonism. Pharmacology . 1974; 12 65-73
- 28 Fann W E, Lake C R. Amantadine versus trihexyphenidyl in the treatment of neuroleptic induced parkinsonism. Am J Psychiatry . 1976; 133 940-943
- 29 Shoulson I. Carbidopa/levodopa therapy of coexisting drug induced parkinsonism and tardive dyskinesia. Adv Neurol . 1983; 37 259-265
- 30 Adler L A, Angrist B, Rotrosen J. Acute neuroleptic-induced akathisia. In: Lang AE, Weiner W, eds. Drug-Induced Movement Disorders
Mount Kisco, NY: Futura Publishing Co 1992: 85-119
MissingFormLabel
- 31 Barnes T RE, Brando W M. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry . 1985; 42 874-878
- 32 Nordstrom A L, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) . 1992; 106 433-438
- 33 Farde L, Nordstrom A, Weisel F. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry . 1992; 49 539-544
- 34 Baldessarini R J, Cole J O, Davis J M. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. Am J Psychiatry . 1980; 137 1163-1172
- 35 Jeste D V, Lacro J P, Palmer B. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry . 1999; 156 309-311
- 36 Fenn D S, Moussaoui D, Hoffman W F. Movements in nevermedicated schizophrenics: a preliminary study. Psychopharmacology (Berl) . 1996; 123 206-210
- 37 Marsden C D. Is tardive dyskinesia a unique disorder?. In: Casey DE, ed. Dyskinesia Research and Treatment
Psychopharm Suppl 2. Berlin: Springer-Verlag 1985: 64-71
MissingFormLabel
- 38 Khot V, Wyatt R J. Not all that moves is tardive dyskinesia. Am J Psychiatry . 1991; 148 661-666
- 39 Jeste D V, Caligiuri M P. Tardive dyskinesia (review). Schizophr Bull . 1993; 19 303-315
- 40 Gold J M, Egan M F, Kirch D G. Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings. Biol Psychiatry . 1991; 30 587-599
- 41 Mion C C, Andreasen N C, Arndt S, Swayze II W V, Cohen G A. MRI abnormalities in tardive dyskinesia. Psychiatry Res . 1991; 40 157-166
- 42 Steen V M, Lovlie R, MacEwan T, McCreadie R G. Dopamine D3receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry . 1997; 2 86-88
- 43 Jankovic J. Tardive syndromes and other drug induced movement disorders. Clin Neuropharmacol . 1995; 18 197-214
- 44 Weiner W J, Goetz C G, Paul A N, Klawans H L. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med . 1978; 88 327-331
- 45 Gardos G, Cole J O, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry . 1978; 135 1321-1324
- 46 Gardos G, Cole J O. Overview: public health issues in tardive dyskinesia. Am J Psychiatry . 1980; 137 776-781
- 47 Hitri A, Weiner W, Borison R. Dopamine binding following prolonged haloperidol pretreatment. Ann Neurol . 1978; 3 134-140
- 48 Jeste D V, Wyatt R J. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?. J Clin Psychiatry . 1981; 42 455-457
- 49 May Reynolds P G, Brown J E, McCall J C, Mackay A V. Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a postmortem study. J Neural Transm Gen Sect . 1992; 87 225-230
- 50 Anderson U, Eckernas S A, Harting P. Striatalbinding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. J Neural Transm Gen Sect . 1990; 79 215-226
- 51 Pahl J J, Mazziotta J C, Bartzokis G. Positron-emission tomography in tardive dyskinesia. J Neuropsychiatry Clin Neurosci . 1995; 7 457-465
- 52 Jankovic J, Beach J. Longterm effects of tetrabenazine in hyperkinetic movement disorders. Neurology . 1997; 48 358-362
- 53 Fahn S. Long term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. Adv Neurol . 1983; 37 267-276
- 54 Klawans H L, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry . 1974; 27 941-947
- 55 Tamminga C A, Crayton J, Chase T. Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiatry . 1979; 36 595-598
- 56 Lieberman J A, Alvin J, Mukherjee S, Kane J M. Treatment of tardive dyskinesia with bromocriptine: a test of the receptor modification strategy. Arch Gen Psychiatry . 1989; 46 908-913
- 57 Stewart R M, Rollins J, Beckham B, Roffman M. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol . 1982; 5 365-373
- 58 Thaker G K, Nguyen J A, Strauss M E. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry . 1990; 147 445-451
- 59 Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardivedyskinesia. J Clin Pharmacol . 1990; 10 414-416
- 60 Loonen A J, Verwey H A, Roels P R, Van Bavel P L, Doorschot C H. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients?. J Clin Psychopharmacol . 1992; 12 39-42
- 61 Elkashef A M, Ruskin P E, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry . 1990; 147 4:505-506
- 62 Lohr J B, Caligiuri M P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry . 1996; 57 167-173
- 63 Shiriqui C L, Bradwejn J, Annable L, Jones B D. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry . 1992; 149 391-393
- 64 Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol . 1995; 36S-44S (36S-44S)
- 65 Gwinn K A, Caviness J N. Risperidoneinduced tardive dyskinesia and parkinsonism. Mov Disord . 1997; 12 119-121
- 66 Anand V S, Dewan M J. Withdrawalemergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry . 1996; 8 179-182
- 67 Burke R E, Kang U J, Jankovic J, Miller L G, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord . 1989; 4 157-175
- 68 Schilkurt V R, Duran E, Haverbeck C, Katz I, Vidal P. Verlauf von psychopathologischen und extrapyramidalmotorischen symptomen unter einer Langzeit-Neuroleptika behandlung schizophrener Patienten. Drug Res . 1978; 28 1484-1495
- 69 Lang A E. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Mov Disord . 1994; 9 188-192
- 70 Burke R E, Fahn S, Jankovic J. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology . 1982; 32 1335-1346
- 71 Keegan D L, Rajput A H. Drug induced dystonia tarda: treatment with L-dopa. Dis Nerv Sys . 1973; 38 167-169
- 72 Sethi K D, Hess D C, Harp R J. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord . 1990; 5 319-321
- 73 Yassa R, Nair V, Dimitor R. Prevalence of tardive dystonia. Acta Psychiatr Scand . 1986; 73 629-633
- 74 Van Harten N P, Matroos G E, Hoek H W, Kahn R S. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res . 1996; 19 195-203
- 75 Kang U J, Burke R E, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord . 1986; 1 193-208
- 76 Kiriakakis V, Bhatia K, Quinn N P, Marsden C D. The natural history of tardive dystonia: a long term follow-up study of 107 cases. Brain . 1998; 121 2053-2066
- 77 Wojick J D, Falk W E, Fink J S, Cole J O, Gelenberg A J. A review of 32 cases of tardive dystonia. Am J Psychiatry . 1991; 148 1055-1059
- 78 Sethi K D, Hess D C, Harmon D. Reverse obstructive sleep apnea syndrome. Neurology . 1988; 312 (312)
- 79 Sachdev P. Tardive and chronically recurrent oculogyric crises. Mov Disord . 1993; 8 93-98
- 80 Bressman S B, de Leon D, Raymond D. Secondary dystonia and the DYTI gene. Neurology . 1997; 48 1571-1577
- 81 Tarsy D, Kaufman D, Sethi K D. An open-label study of botulinum toxin A for treatment of tardive dystonia. Neuropharmacology . 1997; 20 90-93
- 82 Wang Y, Turnbull I, Calne S, Stoessl A J, Calne D B. Pallidotomy for tardive dyskinesia. Lancet . 1997; 349 777-778
- 83 Stahl S. Tardive Tourette syndrome in autistic patients after long term neuroleptic administration. Am J Psychiatry . 1980; 137 1267-1269
- 84 Muller J, Aminoff M J. Tourette like syndrome after long term neuroleptic drug treatment. Br J Psychiatry . 1982; 141 191-193
- 85 Bharucha K J, Sethi K D. Tardive tourettism after exposure to neuroleptic therapy. Mov Disord . 1995; 10 791-793
- 86 Tominaga H, Fukuzako H, Izumi K. Tardive myoclonus. Lancet . 1987; 1 322
- 87 Little J T, Jankovic J. Tardive myoclonus. Mov Disord . 1987; 2 307-311
- 88 Stacy M S, Jankovic J. Tardive tremor. Mov Disord . 1992; 1 53-57
- 89 Meltzer H Y. New drugs for the treatment of schizophrenia. Schizophrenia . 1993; 16 365-385
- 90 Lieberman J A, Saltz B L, Johns C A, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry . 1991; 158 503-510
- 91 Factor S A, Friedman J H. The emerging role of clozapine in the treatment of movement disorders. Mov Disord . 1997; 12 483-496
- 92 Tollefson G D, Beasley Jr M C, Tamura R N, Tran P V, Potvin J H. Blind, controlled, long-term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry . 1997; 154 1248-1254
- 93 Miller D D, Shafruddin M JA, Kathol R G. A case of clozapine induced neuroleptic malignant syndrome. J Clin Psychiatry . 1991; 52 99-101
- 94 Bak T H, Bauer M, Schaub R T, Hellweg R, Reischies F M. Myoclonus in patients treated with clozapine: a case series. J Clin Psychiatry . 1995; 56 418-422
- 95 Bharucha K J, Zamrini E, Evans D, Durrell D, Sethi K D. Clozapine-induced asterixis. Neurology . 1996; 46 A262
- 96 Smego R A, Durack D T. The neuroleptic malignant syndrome. Arch Intern Med . 1982; 142 1183-1185
- 97 Friedman J H. Recognition and treatment of neuroleptic malignant syndrome. Curr Opin Neurol Neurosurg . 1988; 1 310-311
- 98 Burke R E, Fahn S, Mayeux R. Neuroleptic malignant syndrome caused by dopamine depleting agents in a patient with Huntington's disease. Neurology . 1981; 31 1022-1026
- 99 Friedman J H, Feinberg S S, Feldman R G. Neuroleptic malignant like syndrome due to levodopa therapy withdrawal. JAMA . 1985; 254 2792-2795
- 100 Granato J E, Stern B J, Ringel A. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Ann Neurol . 1983; 14 89-90
- 101 Rodriguez M E, Luquin M R, Lera G. Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion. Mov Disord . 1990; 5 170-172